Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
AGNPF ALGERNON PHARMACEUTICALS INC
1.650+0.070+4.43%
Close
02/03 16:00 ET
High
1.650
Open
1.650
Turnover
250.80
Low
1.650
Pre Close
1.580
Volume
152.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Decreases By 26.3%
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) was the target of a large drop in short interest in the month of December. As of December 30th, there was short interest totalling 1,400 sha
A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Starts Dosing
Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB:AGNPF)'s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed the first subject in its Phase 1 clinical stu
Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
VANCOUVER, British Columbia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage ph
Algernon Appoints Dicpinigaitis to Chronic Cough Research Advisory Board
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
The psychedelics space is up and running. Together with the start of the new year, two companies have shared their latest financial decisions toward advancing their medical business programs. Blackhaw
Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement With U.S. SEC for Regulation A+ Offering
VANCOUVER, British Columbia, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Sees Significant Increase in Short Interest
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalli
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Part one of a three-part series. The first medical-grade drug candidate of the psychedelic ayahuasca is being developed. Currently in the form of a pill, the compound was conceived by Vancouver, BC-ba
Short Interest in Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF) Declines By 69.2%
Algernon Pharmaceuticals Inc. (OTCMKTS:AGNPF – Get Rating) saw a significant decline in short interest in November. As of November 30th, there was short interest totalling 1,600 shares, a decline of
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the "Company" or "Algernon") (CSE:AGN) (FRANKFURT: AGW0) (OTCQB:AGNPF), a Canadian clinical stage pharmaceutical development
Company Overview
More
Algernon Pharmaceuticals, Inc. is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them into new human trials, developing new formulations and seeking new regulatory approvals in global markets. It specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. The company was founded on January 22, 2015 and is headquartered in Vancouver, Canada.
CEO： --
Market： Pink Market
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet